Previous 10 | Next 10 |
Completed enrollment in ZEPHYRUS-1 Phase 3 study of pamrevlumab in idiopathic pulmonary fibrosis 1Q 2022 revenue of $60.8M, growth of 58% vs. 1Q 2021 Significant roxadustat volume growth in China in first quarter 2022 offsetting NRDL price reduction S...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips We’re starting off another week of trading with an overview of the biggest pre-market stock mover for Monday! Source: Eric Urquhart/Shutterstock.com News moving stocks this morning include clinical trial resu...
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF continues its investigation into FibroGen, Inc. (NasdaqGS: FGEN). On April 6, 2021, the Company disclosed that cardiova...
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into FibroGen, Inc. (NasdaqGS: FGEN). On April 6, 2021, the Company disclosed that cardi...
SAN FRANCISCO, April 25, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its first quarter 2022 financial results on Monday, May 9 after the market close. FibroGen will also conduct a conference call on that day at 5:00 p.m. ET (2:00 p.m. PT) with the investment communi...
- 356 IPF Patients Enrolled - - Topline Data Anticipated Mid-2023 - SAN FRANCISCO, April 20, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced completion of patient enrollment for ZEPHYRUS-1, the first of two Phase 3 clinical studies of pamrevluma...
Shares of FibroGen Inc (NASDAQ:FGEN) traded today at $68.20, eclipsing its 52-week high. So far today approximately 47.6 million shares have been exchanged, as compared to an average 30-day volume of 790,000 shares. In the past 52 weeks, FibroGen Inc share prices are bracketed by a curre...
Over 10 million people are stricken by cancer each year, with as much as 60% suffering from loss of appetite or anorexia and wasting disease or cachexia. With no standard of care available to treat patients with cancer-related anorexia, there is an eager patient population ready for a...
The following slide deck was published by FibroGen, Inc. in conjunction with their 2021 Q4 earnings call. For further details see: FibroGen, Inc. 2021 Q4 - Results - Earnings Call Presentation
FibroGen, Inc. (FGEN) Q4 2021 Earnings Conference Call February 28, 2022, 05:00 PM ET Company Participants Michael Tung - VP, Corporate Strategy and IR Enrique Conterno - CEO Juan Graham - CFO Mark Eisner - CMO John Hunter - CSO Thane Wettig - CCO Chris Chung - SVP, China Operations Conferenc...
News, Short Squeeze, Breakout and More Instantly...
SAN FRANCISCO, June 18, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced it will host the second part of its virtual KOL investor event series on Wednesday, June 26, 2024 at 10:00 AM ET. To register, click here . The event will feature Rahul Aggarwal, M.D. (Uni...
2024-06-12 09:44:18 ET USA News Group Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – June 12, 2024 – USA News Group – After looking at public health records for 3.8 million patients with invasive spreading cancer, researchers recently discovere...
FibroGen to evaluate FG-3165, an anti-galectin 9 (Gal9) monoclonal antibody (mAb), as monotherapy treatment as well as in combination with LIBTAYO ® in patients with select solid tumors FibroGen to evaluate FG-3175, an anti-c-c motif chemokine receptor 8 (CCR8) mAb, a...